Thailand FDA SaMD registration: 2026 guide for EU MDR companies

Thailand's medical device market and regulatory framework

Thailand is Southeast Asia's second-largest medical device market and one of the region's most sophisticated healthcare systems, with 77 million people and a rapidly digitising hospital sector. Thailand's Food and Drug Administration (TFDA), operating under the Ministry of Public Health, regulates medical devices under the Medical Device Act B.E. 2562 (2019) and its implementing regulations.

SaMD in Thailand is regulated as a medical device when it has an intended purpose consistent with the definition of a medical device — diagnosis, treatment, monitoring, prevention, or alleviation of disease. TFDA classifies SaMD into three classes (1, 2, 3) based on risk, following IMDRF-aligned risk categorisation principles. Most clinical SaMD — diagnostic algorithms, clinical decision support, monitoring platforms — classifies as Class 2 or 3.

TFDA's SaMD-specific guidelines

Thailand's FDA issued specific SaMD registration guidelines that establish documentation requirements tailored to software. For Class 1 SaMD (lowest risk), TFDA implemented an auto-approval process from January 2025 for listed device categories — registration number issued automatically once required documents and fees are received.

For Class 2 and Class 3 SaMD, documentation requirements include:

• Product description and intended use: Specific, detailed statement of intended medical purpose, user population, clinical context, and contraindications
• Risk analysis documentation: ISO 14971-aligned risk management file showing hazard identification, risk estimation, control measures, and residual risk assessment
• Quality system certificate: ISO 13485 certification or equivalent QMS evidence. EU MDR Class IIa/IIb NB certificate demonstrates QMS compliance
• Registration history in reference markets: EU MDR CE mark certificate, FDA clearance, or other major market approvals. TFDA treats these as strong evidence of safety and performance
• Cybersecurity documentation: For connected SaMD, cybersecurity risk assessment and controls documentation. TFDA aligns with international cybersecurity guidance for medical devices
• Clinical evidence summary: Performance data demonstrating the software's clinical accuracy and safety in its intended use — your EU MDR Clinical Evaluation Report summary serves this purpose

The Malaysia–Thailand regulatory reliance pilot 2026

On 4 December 2025, Malaysia's MDA and Thailand's FDA announced a regulatory reliance pilot running from February 1 to April 30, 2026. Under this pilot, devices registered with Thailand FDA can access the Malaysian Verification Route, and MDA-approved devices receive expedited Thai registration.

For SaMD companies already registered in both Malaysia (via EU MDR reference) and Singapore (via HSA), the Malaysia–Thailand pilot creates a multi-market cascade: EU MDR → Singapore HSA (3–9 months) → Malaysia MDA via Verification Route (3 months) → Thailand FDA via Malaysia reliance pilot → Philippines via Singapore reference. This ASEAN cascade — starting from one EU MDR certification — can cover four markets in sequence with each market building on the previous approval.

Standard TFDA registration process for EU MDR certified SaMD

Outside of the reliance pilot, EU MDR certified SaMD companies can register with TFDA through the standard pathway using EU NB certificate as reference evidence:

1. Appoint a Thai Importer/Distributor: All non-Thai manufacturers must have a licensed Thai importer who submits the registration application and holds the product licence. The importer must hold a medical device licence from TFDA.
2. Determine Thai device class: TFDA will assign a class based on the product's intended use and risk. Confirm the Thai classification matches your intended use statement before submission — classification disputes require documentation of clinical rationale.
3. Prepare Thai submission package: Product description, risk analysis, QMS certificate, registration history (EU MDR certificate), clinical evidence, cybersecurity documentation (for connected SaMD), Thai labelling compliant with TFDA requirements, and power of attorney from manufacturer to Thai importer.
4. Submit through e-Submission: TFDA operates an electronic submission system. Your Thai importer manages portal access and submission.
5. Timeline: Class 2 SaMD: approximately 12–18 months for complete submissions. EU MDR reference typically reduces query frequency and speeds review. Class 1 auto-approval: days to weeks.

Thai labelling requirements for SaMD

Thai labelling must be in Thai language or bilingual (Thai–English). For professional-use SaMD deployed in clinical settings, Thai language labelling requirements apply to: product name, manufacturer name and address, Thai importer name and address, intended use statement, and TFDA product registration number once issued. Instructions for Use for professional SaMD can typically remain in English with a Thai-language summary.